Skip to main content

RadNet to Host Men’s Health Webinar on June 13, 2026

Free public event during National Men’s Health Month features leading physicians addressing coronary artery disease, prostate cancer and lung cancer

LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of over 440 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, June 13, 2026, in recognition of National Men’s Health Month. The event will feature presentations by radiologists on three of the most significant health conditions affecting American men today: coronary artery disease, prostate cancer and lung cancer.

The clinical case for increased attention to men’s health is well established. Heart disease remains the leading cause of death for American men, with more than 52% of men over the age of 20 living with some form of cardiovascular disease.1 Prostate cancer — the second most commonly diagnosed cancer in men globally — affects 1 in 8 men, with more than 50% of risk tied to genetics.2 Lung cancer remains the leading cause of cancer-related death among men, yet only 28.1% of cases are diagnosed at an early stage, when treatment options are most effective.3 Across all three conditions, early detection is critical for improved outcomes. Men should talk to their physicians about potentially starting screening at 40 years for heart disease, 45 years for prostate cancer and 50 years for lung cancer.

The June 13 webinar will provide patients with accessible, physician-led education on risk factors, screening criteria and the role of diagnostic imaging in early detection. Attendees will also have the opportunity to participate in a live question and answer discussion with the physicians. Speakers include:

  • Michael G. Coords, MD, FSCCT, Medical Director, California, will present on coronary artery disease, offering a clinical overview of risk identification and the imaging tools available to detect disease before a cardiac event occurs.
  • Randall Stenoien, MD, Medical Director, Texas, will present on advances in prostate MRI and AI for early detection of prostate cancer.
  • Evan Kaminer, MD, FACR, Medical Director, New York, will present on low-dose CT for lung cancer screening and its benefits for high-risk asymptomatic patients.

“Men’s health is one of the most underdiscussed areas of preventive care, and we built this event specifically to close that gap,” said Gregory Sorensen, MD, Executive Vice President and Chief Strategy Officer, RadNet. “At RadNet, we believe that access to the latest information is just as important as access to the imaging technology itself. Early detection can save lives, and events like this are how we put that belief into action.”

RadNet operates more than 435 outpatient imaging centers across 11 states, providing patients with convenient access to advanced diagnostic imaging services, including cardiac CT, prostate MRI and low-dose lung CT screening. The company’s AI-enhanced imaging technology and network of expert radiologists deliver accurate, timely results to support clinical decision-making and, where applicable, early intervention.

Event Details
The webinar is free to attend and open to all.

  • Date: Saturday, June 13, 2026
  • Time: 10-11 a.m. PDT // 1-2 p.m. EDT
  • Register: www.radnet.com/webinars/mens-health

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
jane.mazur@radnet.com  

References

      1)   Martin SS, et al., “2025 Heart Disease & Stroke Statistical Update Fact Sheet Males & Cardiovascular Diseases.” American Heart Association. January 2025.

      2)   “Key Statistics for Prostate Cancer.” American Cancer Society. January 2026.

      3)   “New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress.” American Lung Association. November 2025.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.